HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Playtex

This article was originally published in The Rose Sheet

Executive Summary

Playtex: Looking to broaden H&BA and OTC portfolio through acquisitions of brands or companies, or by leveraging the Playtex name on new products, the company said. Dallas-based Hass, Wheat & Partners, which holds a 40% stake in Playtex, is also investigating strategic options for the company. Playtex said it would like to augment sales by $100 mil. by mid-1998 and by $250 mil. by mid-1999. The company's decision to diversify further may be in part a response to P&G's April 9 announcement that it will acquire tampon category leader Tambrands ("The Rose Sheet" April 14, In Brief). Playtex is already making headway in diversifying its revenue base -- for the first quarter of 1997, sun care (Banana Boat and BioSun) sales jumped 32.4% to $43.7 mil., representing 32% of the company's $136.4 mil. business. The company's feminine care unit, on the other hand, slumped 32.7% to $39.1 mil., accounting for 28.7% of sales. In the 1996 first quarter, the segments represented 23.1% and 40.6% of Playtex sales, respectively. The company also sells Jhirmack haircare products Tek toothbrushes, Playtex infant care goods, Playtex household gloves and Woolite carpet cleaner. Playtex' business is heavily weighted to the U.S. and Canada; the two countries account for 95% of the company's revenue...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel